Problems › Our Marketing Spend Is Not Working › Healthcare Providers
Most marketing that "does not work" is spend on a channel that cannot reach the buyer, measured in a way that cannot tell. This page works through it for healthcare providers specifically — including an unedited excerpt from a real analysis of a healthcare provider.
Most marketing that "does not work" is spend on a channel that cannot reach the buyer, measured in a way that cannot tell. Healthcare providers carry a specific bind here — downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Until that is priced, cost per episode will keep moving for reasons nobody can attribute, and the debate about CAC by channel will stay a matter of opinion.
Two different failures produce the same complaint. The channel genuinely does not reach your buyer, in which case more budget makes it worse. Or it does and you cannot see it, in which case the spend is being judged by a measurement system that does not track the path your buyer actually takes.
Separating them is a measurement question first. If cost per acquisition cannot be computed by channel, no amount of creative or targeting work will settle the argument, and the budget will be allocated by whoever is most confident.
The second question is payback rather than volume. A channel that acquires expensively but pays back inside a quarter is fundable; one that acquires cheaply and pays back in three years is not, whatever the cost per lead says.
These three together are the signature. One on its own usually points somewhere else.
✓ Cost per acquisition cannot be stated by channel
✓ Spend is defended by impressions, clicks or leads rather than by customers
✓ The best-performing channel changes depending on who reports it
The move that usually makes it worse. Optimising creative and targeting before fixing measurement, which produces a year of confident decisions on unreliable numbers.
It is for you if you run or finance a healthcare provider and cost per acquisition cannot be stated by channel. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Protect and grow the 34% operating-income ASC engine by replacing retiring surgeons and steering 212k attributed lives to the ASC within 24 months.
| Investment required | $3.0-4.0M total over 24 months ($1.8-2.2M surgeon succession + retention bonuses; $1.2-1.8M referral-optimization platform and analytics) |
| Expected return | Incremental $4.8-6.4M annual ASC contribution margin by Month 24; payback 14-18 months on $3.0-4.0M investment; lifts group operating margin from 4.2% to 5.8-6.4%. |
| Revenue, year 1 | $202-208M (ASC case volume +4-6%) |
| Revenue, year 2 | $212-220M (ASC case volume +6-8%; physician retention +2-3%) |
| Revenue, year 3 | $225-235M (ASC contribution ≥40% of operating income) |
| Exit criteria | Strategy abandoned if, by Month 12, fewer than two qualified orthopaedic surgeon candidates have signed LOIs OR if ASC case volume has not grown at least 2% YoY; in either case, board must decide within 30 days whether to pivot to hospital-system sale process at 8-10× EBITDA. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
The only meaningful test is against lifetime value and payback period, both of which are business-specific. A cost that is excellent in one model is ruinous in another with the same revenue.
Long enough to cover your sales cycle plus one payback period, and no longer. Judging early kills channels that work slowly; judging late funds channels that never will.
Cut the channels you cannot measure first — that is where the risk is concentrated. Cutting uniformly removes the channel that was working alongside the ones that were not.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.